Susanne Albrecht

Centre of Registers Vastra Gotaland

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

J. Schüttler

Universitätsklinikum Erlangen

Harald Ihmsen

Universitätsklinikum Erlangen

W. Hering

University Hospital Frankfurt

H. Schwilden

Friedrich-Alexander-Universität Erlangen-Nürnberg

Wolfgang Janni

University Hospital Ulm

Thomas W. P. Friedl

University Hospital Ulm

J. Fechner

Friedrich-Alexander-Universität Erlangen-Nürnberg

Peter A. Fasching

Comprehensive Cancer Center Erlangen

Thomas F. Hany

University of Zurich

Tanja Fehm

Heinrich Heine University Düsseldorf

Cooperative Institutions

Klinik für Frauenheilkunde

Ludwig-Maximilians-Universität München

Friedrich-Alexander-Universität Erlangen-Nürnberg

Heidelberg University

Universität Ulm

University Hospital Heidelberg

University Hospital Ulm

Heinrich Heine University Düsseldorf

University of Bonn

Universitätsklinikum Erlangen

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Acquired von Willebrand Syndrome during Mechanical Circulatory Support and Extracorporeal Membrane Oxygenation: Rapid Onset and the Demand for Point of Care Testing

Hämostaseologie (2019)

Kurt Hohenstein M. Straussinsky Patricia Schüssel Tiago Granja Iván Vollmer

Introduction: Unexplained bleeding episodes are frequently observed in patients being treated with mechanical circulatory support (MCS) and extracorporeal membrane oxygenation (ECMO), and this is often associated with acquired von Willebrand syndrome (AVWS). AVWS is characterized by loss of high molecular weight (HMW) multimers of von Willebrand factor (VWF) and decreased ratios of collagen binding capacity to VWF as a result of high shear stress, which results in diminished binding to collagen and to the platelets. The aim of this observational study is to analyze the AVWS coagulopathie in intensive care patients supported by different MCS systems.

von Willebrand Disease

10.1055/s-0039-1680116

Cite

Citations (0)

Rapid Offset of Effects with Remifentanyl after 10 days of continuous infusion

Intensive Care Medicine (2004)

Manu L. N. G. Malbrain Andreas Karabinis Rex J. Morais Susanne Albrecht I.L. Jarnvig

Pain medicine

Source

Cite

Citations (0)

„Target controlled infusion“ (TCI) – ein Konzept mit Zukunft?: Standortbestimmung, Handlungsempfehlungen und Blick in die Zukunft

Der Anaesthesist (2008)

Stefan Schraag Sascha Kreuer Jörgen Bruhn C. Frenkel Susanne Albrecht

Source

Cite

Citations (5)

Prädiktivität und Präzision einer „target-controlled infusion” (TCI) von Propofol mit dem System „Disoprifusor TCI®”

Der Anaesthesist (1998)

J. Fechner Susanne Albrecht Harald Ihmsen Ralph Knöll H. Schwilden

Target controlled infusion

10.1007/s001010050611

Cite

Citations (44)

RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina (2017)

Inger Westborg Susanne Albrecht Aldana Rosso

Purpose: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice. Methods: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patients' characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years. Results: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug. Conclusion: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.

10.1097/iae.0000000000001431

Cite

Citations (15)

Morbidity and Mortality of Patients with Spontaneous Intracerebral Hematoma

Advances in neurosurgery (1993)

J. Nadstawek Josef Zentner U Ruta Susanne Albrecht B. Kaden

Spontaneous intracerebral hemorrhage

Intracerebral hematoma

Level of consciousness

10.1007/978-3-642-77997-8_17

Cite

Citations (0)

[Target-controlled infusion (TCI) - a concept with a future?: state-of-the-art, treatment recommendations and a look into the future].

PubMed (2008)

Stefan Schraag Sascha Kreuer Jörgen Bruhn C. Frenkel Susanne Albrecht

Target controlled infusion

Clinical Practice

10.1007/s00101-008-1329-7

Cite

Citations (12)

Copeptin als Parameter zur Vorhersage einer kurzfristigen Hochrisikoprognose bei Patienten mit ambulant erworbener Pneumonie

Pneumologie (2013)

Martin Kolditz Michael Halank Bernhard Schulte-Hubbert S. Bergmann Susanne Albrecht

Einleitung: Die optimale Risikoprädiktion eines kurzfristigen ungünstigen Verlaufs bei Patienten mit ambulant erworbener Pneumonie (CAP) mit klinischen Scores und Biomarkern ist nicht zufriedenstellend gelöst. Die neuen kardiovaskulären Marker Copeptin und Proadrenomedullin (MR-proADM) sind vielversprechend zur Evaluation der mittel- und längerfristigen Prognose bei CAP. Diese prospektive Studie evaluiert beide Marker erstmals hinsichtlich ihrer prognostischen Wertigkeit zur Vorhersage kurzfristiger klinischer Hochrisikoendpunkte.

Copeptin

10.1055/s-0033-1345066

Cite

Citations (0)

The Superficial Cervical Plexus Block for Postoperative Pain Therapy in Carotid Artery Surgery. A Prospective Randomised Controlled Trial

European Journal of Vascular and Endovascular Surgery (2006)

Michael Messner Susanne Albrecht Werner Lang Reinhard Sittl M. Dinkel

Ropivacaine

Cervical plexus

Endarterectomy

10.1016/j.ejvs.2006.06.024

Cite

Citations (37)

Plasma Testosterone and Sexual Function in Men Receiving Buprenorphine Maintenance for Opioid Dependence

The Journal of Clinical Endocrinology & Metabolism (2005)

N. Bliesener Susanne Albrecht Andra Schwager Klaus Weckbecker Dirk Lichtermann

High-dose methadone is well known to cause testosterone deficiency and sexual dysfunction in opioid-dependent men. Buprenorphine is a new drug for the pharmacotherapy of opioid dependence. Its influence on the gonadal axis has not been investigated to date. We therefore assayed testosterone, free testosterone, estradiol, SHBG, LH, FSH, and prolactin in 17 men treated with buprenorphine. Thirty-seven men treated with high-dose methadone and 51 healthy blood donors served as controls. Sexual function and depression were assessed using a self-rating sexual function questionnaire and the Beck Depression Inventory. Patients treated with buprenorphine had a significantly higher testosterone level [5.1 +/- 1.2 ng/ml (17.7 +/- 4.2 nmol/liter) vs. 2.8 +/- 1.2 ng/ml (9.7 +/- 4.2 nmol/liter); P < 0.0001] and a significantly lower frequency of sexual dysfunction (P < 0.0001) compared with patients treated with methadone. The testosterone level of buprenorphine-treated patients did not differ from that of healthy controls. In conclusion, we demonstrated for the first time that buprenorphine, in contrast with high-dose methadone, seems not to suppress plasma testosterone in heroin-addicted men. To this effect, buprenorphine was less frequently related to sexual side effects. Buprenorphine might therefore be favored in the treatment of opioid dependence to prevent patients from the clinical consequences of methadone-induced hypogonadism.

10.1210/jc.2004-0929

Cite

Citations (231)